Covalent Modifiers

OCTOBER 12, 2024

Here, we optimized a CHIKV nsP2 protease (nsP2pro) biochemical assay for the screening of a 6,120-compound cysteine-directed covalent fragment library. CHIKV nonstructural protein 2 (nsP2), which contains a cysteine protease domain, is essential for viral replication, making it an attractive target for a drug discovery campaign.

Virus

Drug Target Review

JANUARY 10, 2024

The Transcreener HTS Assay platform accelerates these efforts by providing robust and easy-to-use biochemical assays for key enzymes in the pathways. In this guide, we provide an overview of the DDR and innate immune pathways and describe assay systems for key therapeutic targets.

DNA

Covalent Modifiers

MARCH 17, 2023

Biochemical assays and X-ray crystallographic studies validated the ternary covalent complex formation and overall PPI stabilization via dynamic covalent crosslinking. The PPI between the hub protein 14-3-3 and estrogen-related receptor γ (ERRγ) was used as a pharmacologically relevant case study.

Biochemical Assays

Chemical Biology and Drug Design

MAY 17, 2024

Using fungal tyrosinase-based in vitro biochemical assay, we obtained one compound ( 3k ) which could inhibit tyrosinase activity, and the other compound ( 4f ) that stimulated tyrosinase activity. In the present study, we investigated these compounds for their potential as antagonists or agonists of tyrosinase.

Biochemical Assays

ASPET

DECEMBER 21, 2023

Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemical assays.

Biochemical Assays

Chemical Biology and Drug Design

JANUARY 23, 2024

Then, cardiac function parameters were assessed using echocardiography, myocardial injury markers were quantified via biochemical assays, and myocardial histopathological injuries were observed through H&E staining.

Biochemical Assays

Drug Target Review

NOVEMBER 1, 2023

We often screen using a biochemical assay, but we can conduct cell-based screening as well. For fragment screening, we can screen with biophysical methods, such as thermal shift assays or, you may have heard about Surface Plasmon Resonance (SPR) which is a very sensitive biophysical technique used for fragment screening.

Fragment Screening

Molecular Design

SEPTEMBER 18, 2024

In the Compatibility Issues section the authors state: Looking beyond laboratory-to-laboratory variability of assays that are nominally the same, there are numerous reasons why literature results for different assays measured against the same “target” may not be comparable.

Biochemical Assays

Molecular Design

JULY 18, 2020

One point that comes out of Pat’s post is that it’s difficult to establish structure-activity relationships for low affinity ligands with a conventional biochemical assay. This is one reason that biophysical detection of binding using methods such as surface plasmon resonance (SPR) are favored in fragment-based lead discovery.

Biochemical Assays

PerkinElmer

FEBRUARY 18, 2021

Biochemical assays have the highest success rate. The top 20 Pharma are moving away from proteins in biochemical assays and overexpressed targets in simple cell lines toward more physiologically relevant assays using primary cells, cocultures, 3-D cell systems, or organoids. Biologics are booming. Think again.

Biochemical Assays

The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

Additionally, Strateos' Senior Director of R&D Strategy, Daniel Rines, Ph.D.,  will be participating in a panel discussion during SLAS2022 February 7th 4:30-6:00pm EST alongside other thought leaders to discuss artificial intelligence in labs now and in the future.

Biochemical Assays

Molecular Design

DECEMBER 19, 2023

Carefully designed biochemical assays used in determining IC50 values can be well-suited as surrogates for k.inact/K.i [The labor-intensive nature of the measurements is not a valid justification for a failure to measure k.inact and K.i values for a covalent chemical probe.] measurements. ( values for the inhibitor.]

Small Molecule

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays.

Small Molecule

Practical Cheminformatics

AUGUST 3, 2023

Initially, I would recommend aqueous solubility, membrane permeability, in vitro metabolic stability, and biochemical assays. Focus benchmarking efforts on simple, robust, relevant, clearly defined endpoints. These endpoints are reproducible, relatively inexpensive, and can provide reasonably large datasets.

Drugs

Molecular Design

DECEMBER 6, 2023

I’ll be taking a look at B2023 (Fused Tetrahydroquinolines Are Interfering with Your Assay) in this post. The article has already been discussed in posts at Practical Fragments and In The Pipeline.

Biochemical Assays

Agency IQ

JUNE 26, 2023

Further, footnote 7 in the document explains: “Examples of such clinical laboratory tests are commonly used and well understood biochemical assays (e.g., As the 2014 definitions document states (footnote 6): “Uses of diagnostic devices that are suggested but not required in therapeutic product labeling are not considered essential.””

FDA

Agency IQ

APRIL 12, 2024

Assays are tests designed to assess various properties (like potency) of chemical or biological samples.

Production

Drug Target Review

DECEMBER 8, 2023

In our project, we used biochemical assays to identify which proteins interact with Rnf43.” “We wanted to know how Rnf43 works, and also what – in turn – controls Rnf43 and helps it to regulate Wnt signalling.” A crucial partner of Rnf43 turned out to be the protein Daam1.

Biochemical Assays

Covalent Modifiers

MAY 2, 2025

Glecirasib exhibited high potency against KRAS G12C, along with a high level of selectivity over the wild-type KRAS, HRAS, and NRAS in biochemical assays. In the current study, we report the preclinical characteristics of a specific KRAS p.G12C covalent inhibitor, glecirasib.

Biochemical Assays

Chemical Biology and Drug Design

APRIL 3, 2025

Subsequent rounds of in silico docking, medicinal chemistry optimization, and biochemical assays were performed to increase its potency and selectivity for SRPK3. Six top compounds were identified that displayed single digit micromolar IC 50 values in SRPK3 activity assays and negligible inhibition of SRPK1 or SRPK2.

Biochemical Assays